Could MPDL3280A offer a therapeutic breakthrough in metastatic bladder cancer?

Nature Reviews Urology

Volumn 12, Issue 2, 2015, Pages 61-

  Fenner, Annette ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; MPDL 3280A; PROGRAMMED DEATH 1 LIGAND 1; MONOCLONAL ANTIBODY;

ASSESSMENT OF HUMANS; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL INFILTRATION; CREATININE CLEARANCE; DISEASE ERADICATION; EASTERN COOPERATIVE ONCOLOGY GROUP SCORE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT RESPONSE; TUMOR VOLUME; UROTHELIAL BLADDER CANCER; FEMALE; IMMUNOTHERAPY; MALE; URINARY BLADDER NEOPLASMS;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; URINARY BLADDER NEOPLASMS;

EID: 84926419796     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.344     Document Type: Short Survey

References (1)

1. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014)